According to Armstrong et al., liraglutide, a GLP-1 receptor agonist, resulted in histological resolution of MASH in 39% of patients, significantly improving insulin sensitivity and reducing hepatic fat content [20]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.